Overview
Liraglutide is a peptide developed by Novo Nordisk. It is sold as Saxenda for weight management and Victoza for type 2 diabetes. Both are prescription medicines given by daily injection.
FDA-approved liraglutide medicines, including generic versions, are available by prescription and should be taken under a doctor’s care.
What is it being studied for?
Research on liraglutide covers weight loss, type 2 diabetes, and reducing the risk of heart attack and stroke in people with diabetes.
Liraglutide acts on the GLP-1 receptor, which helps regulate appetite, insulin release after a meal, and how fast the stomach empties.
What has research found?
In a 56-week study, adults with obesity and no diabetes who received a daily study dose of 3 milligrams lost about 8 percent of their body weight. Those given a placebo lost about 3 percent.
A separate study followed adults with type 2 diabetes and high cardiovascular risk for roughly four years. Heart attack, stroke, or cardiovascular death occurred less often with liraglutide than with a placebo.
Common side effects included nausea, vomiting, and diarrhea. The prescribing information carries a boxed warning about thyroid C-cell tumors found in rodents.
FDA status and development history
Liraglutide is approved for human use. The Food and Drug Administration cleared it in 2010 for type 2 diabetes under the name Victoza and in 2014 for weight management under the name Saxenda. Generic versions are now approved.